

β -lactamase remodeling and evolution of collateral resistance in hypermutator *Pseudomonas aeruginosa* upon long-term antibiotic therapy

Claudia A. Colque^{1,2}, Pablo E. Tomatis^{3,4¶}, Andrea G. Albarracín Orio^{1,2,5¶}, Gina Dotta³,
Diego M. Moreno⁶, Laura G. Hedemann^{1,2}, Rachel A. Hickman^{7,8}, Lea M. Sommer
Madsen^{7,8}, Sofá Feliziani^{1,2}, Alejandro J. Moyano^{1,2}, Robert A. Bonomo^{9,10}, Helle K.
Johansen^{7,8,11}, Søren Molin⁸, Alejandro J. Vila^{3,4*}, Andrea M. Smania^{1,2*}

¹Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Química Biológica Ranwel Caputto, Córdoba, Argentina.

²CONICET, Universidad Nacional de Córdoba, Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), Córdoba, Argentina.

³Instituto de Biología Molecular y Celular de Rosario (IBR), CONICET, Universidad Nacional de Rosario, Rosario, Argentina.

⁴Area Biofísica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Argentina.

⁵IRNASUS, Universidad Católica de Córdoba, CONICET, Facultad de Ciencias Agropecuarias, Córdoba, Argentina

⁶IQUIR, Instituto de Química de Rosario, Universidad Nacional de Rosario, Santa Fe, Argentina

⁷Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark

⁸Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Lyngby, Denmark

⁹Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA

¹⁰Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA

¹¹Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

[¶]These authors contributed equally to this work.

*Correspondence to:

Andrea M. Smania, Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC-CONICET), Universidad Nacional de Córdoba, X5000HUA, Córdoba, Argentina, e-mail: asmania@unc.edu.ar.

Alejandro J. Vila, Universidad Nacional de Rosario, Instituto de Biología Molecular y Celular de Rosario (IBR-CONICET), S2000EZP, Rosario, Argentina, e-mail: vila@ibr-conicet.gov.ar.

Keywords: *Pseudomonas aeruginosa*, cystic fibrosis, ceftolozane resistance, β -lactamase evolution, hypermutability

ABSTRACT

Bacteria are endowed with a unique ability to adapt to challenging environments. The evolution of bacterial populations during chronic infections involves a large diversity of adaptive mechanisms that cannot always be reproduced upon controlled laboratory conditions. This creates a gap between the phenotypical description and the underlying biochemical processes that drive that phenotype. Herein, we address the complexity of the bacterial adaptive response to antibiotic selective pressures by studying the *in-patient* evolution of a broad diversity of β -lactam resistant *Pseudomonas aeruginosa* hypermutator clones. By using mutational and ultra-deep amplicon sequencing analysis, we analyzed multiple generations of a *P. aeruginosa* hypermutator strain persisting for more than 26 years of chronic infection in the airways of a cystic fibrosis patient. We identify the accumulation of multiple alterations targeting the chromosomally encoded class C β -lactamase (*bla_{PDC}*), providing structural and functional protein changes that resulted in a continuous enhancement of its catalytic efficiency and high level of cephalosporin resistance. This evolution was linked to the persistent treatment with ceftazidime, which we demonstrate selected for variants with robust catalytic activity against this expanded-spectrum cephalosporin. Surprisingly, “a gain of function” of collateral resistance towards ceftolozane, a more recently introduced cephalosporin that was not prescribed to this patient, was also observed and the biochemical basis of this cross-resistance phenomenon was elucidated. This work pinpoints the considerable evolutionary potential of hypermutator strains and uncovers the link between the antibiotic prescription history and the *in-patient* evolution of resistance.

SIGNIFICANCE STATEMENT

In the past decade, we have witnessed the evolution of complex host-pathogen interactions in which bacteria display adaptive strategies to counteract standard or novel antibiotic treatments. By using mutational and ultra-deep amplicon sequencing analysis, we studied multiple generations of a *Pseudomonas aeruginosa* hypermutator strain persisting for more than 26 years of chronic infection in the airways of a cystic fibrosis patient. We uncovered a clear association between the antibiotic prescription history and the *in-patient* evolution of resistance; we also provide a biochemical rationale for the evolution of collateral resistance to the unprescribed cephalosporin, ceftolozane. This work unveils the evolutionary trajectory driven by hypermutators towards a multidrug resistant phenotype after years of antibiotic treatment against a formidable pathogen.

.

INTRODUCTION

Our current knowledge regarding the evolution of bacterial antibiotic resistance mainly comes from clinical, microbiological and biochemical studies that are performed under controlled conditions (1-7). Collectively, we have learned that the emergence and evolution of antibiotic resistance, one of the greatest challenges to our civilization, is a far more complex phenomenon; few studies exist that offer insights into “real-world” scenarios that adequately or completely explain evolutionary trajectories that shape existing phenotypes (8-14).

Chronic infections by *Pseudomonas aeruginosa* are main causes of morbidity and mortality in patients suffering from cystic fibrosis (CF). Treating these long-term airway infections is extremely challenging since *P. aeruginosa* displays an intrinsic resistance to many antibiotics, as well as an unwelcome capacity to develop and evolve resistance to newly introduced antibiotics. Acquired antibiotic resistance in CF associated isolates of *P. aeruginosa* occurs mainly through the accumulation of multiple mutations that alter the expression and/or function of different chromosomal genes (15, 16). Furthermore, *P. aeruginosa* hypermutator strains are frequently isolated from CF patients, thus raising the pace of increased antibiotic resistance development (17-21) and the repertoire of adaptability (22-27). Nevertheless, these persistent infections with complex phenotypes offer unique opportunities to study antibiotic resistance evolution since: (i) they are highly influenced by long-term antibiotic treatment to which patients are exposed during their entire lives; (ii) they are often clonal and single *P. aeruginosa* lineages can persist in the lungs of individual patients for many decades; and (iii) *de novo* evolution of antibiotic resistance in individual patients can be monitored constituting an attractive model system for studying the evolution of bacterial populations that strive to adapt to complex dynamic environments (28).

These pulmonary infections with *P. aeruginosa* in patients with CF are intensively treated with a wide repertoire of antipseudomonal antibiotics, including aminoglycosides, quinolones, and β -lactams. In response, *P. aeruginosa* displays a wide arsenal of resistance mechanisms such as reduced outer membrane permeability, upregulation of multiple broad-spectrum drug efflux pumps, antimicrobial modifying enzymes, and target site changes (29). In the case of β -lactam antibiotics, the main resistance mechanism in *P. aeruginosa* is the mutation-mediated overproduction of the chromosomally encoded class C β -lactamase, PDC (*Pseudomonas*-*derived* *c*ephalosporinase). Constitutive overexpression of the *ampC* beta-lactamase gene (thereinafter *bla*_{PDC}) results from mutations affecting regulatory genes of the peptidoglycan recycling process linked to bacterial cell wall assembly (30-34). β -lactam resistance has also been associated with structural modifications of PDC (35-41), as evidenced by the >400 PDC variants that have been described so far (42). This impressive number of allelic variants accounts for a highly polymorphic enzyme with a great capacity of tolerating amino acid substitutions, insertions and deletions (42). Recent studies have shown that clinical resistance to β -lactams is primarily based on specific changes in conserved motifs of PDC, which lead to conformational rearrangements enhancing the catalytic efficiency of the enzyme (38, 43-46).

In a whole-genome sequencing study of hypermutator populations of *P. aeruginosa* during long-term chronic airways infections in a single patient (25), 36 genes in the β -lactam resistome (from a total of 70) carried mutations (47). Specifically, the *bla*_{PDC} gene was targeted by multiple independent mutational events in a process boosted by hypermutability (47) leading to a wide diversity of coexisting *bla*_{PDC} alleles and high-levels of β -lactam resistance, expanding the range of *P. aeruginosa* opportunities for persistence (47). However, the presence of mutations in several genes and the increased

expression of PDC compared to isolates preceding the antibiotic treatment does not permit a direct assessment of the impact of the allelic variability of PDC in resistance. Therefore, dissection of the impact of specific mutations in this gene is of relevance to trace the evolution of this enzyme and consequently to guide future therapies.

Here, we unravel the mutational pathways and biochemical mechanisms involved in different PDC variants by analysing the evolutionary history of more than 25 years of CF chronic infection in a single patient. We show how the combination of substitutions in important amino acid residues in PDC change the architecture of the enzyme active site. This adaptive scenario led to the selection of distinct enzymatic variants which conferred resistance to a broad range of β -lactam antibiotics, even to novel combinations of these drugs that were not prescribed to this patient, such as ceftolozane/tazobactam. We also identify the molecular features that elicited the selection of collateral resistance driven by the use of narrow spectrum cephalosporins, and how this resistance was potentiated by hypermutability in *P. aeruginosa*. By modelling a core of three substitutions preserved in the prevailing variants, we hypothesize that favorable interactions are created between ceftolozane and PDC. This work details the trajectory undertaken on the path towards a multidrug resistant phenotype even against untested drugs and illustrates the “collateral damage” suffered by years of antibiotic treatment against a formidable pathogen.

RESULTS

Long-term evolution of *P. aeruginosa* hypermutator populations leads to the selection of novel *bla_{PDC}* allelic variants with enhanced cephalosporin resistance

In a previous study, the complete genomes of 14 isolates from a hypermutator *P. aeruginosa* lineage spanning 20 years of patient infection history (CFD patient) were sequenced (25). The clonal collection included a non-mutator ancestor from 1991, two hypermutator isolates from 1995 and 2002, and 11 isolates taken from the same sputum sample in 2011, all of them harboring the same *mutS* mutation (25). Within-patient genome comparisons revealed a vast accumulation of mutations that shape an extensively diversified population composed of different sub-lineages, which coexisted from the beginning of the chronic infection. Interestingly, the gene encoding the β -lactamase PDC (*bla_{PDC}*) was among the most frequently altered by mutations across different isolates, suggesting that *bla_{PDC}* was subjected to strong selective pressure (47) (Fig. 1). In fact, during the course of chronic airway infection, the patient received prolonged antibiotic treatment with β -lactam antibiotics (Fig. 1A). The patient initially received short courses of variable duration of cefotaxime, ceftazidime, piperacillin, aztreonam and the carbapenems, thienamycin and meropenem, and then was continuously treated with ceftazidime from 2004 until the end of 2016. Accordingly, a significant increase in the resistance to ceftazidime in these isolates was reported after the prolonged treatment with this antibiotic (Fig. S1), which is evident since 2002 (47).

In an effort to determine the evolution of substrate specificity of the PDC resistant determinant, we tested the resistance of these isolates to ceftolozane-tazobactam, a combination of a cephalosporin and a β -lactamase inhibitor approved in 2014. Even though this combination was not prescribed to this patient (Fig. 1A), the isolates dating back to 2002 were highly resistant to this combination (Fig. S1).

In order to understand the reason for this phenotype, we sequenced *bla_{PDC}* from 19 additional isolates belonging to the selected lineage, resulting in a total of 30 isolates obtained from the same 2011 sputum sample. As shown in Fig. 1B, the ancestor from 1991 and the 1995 isolate harbored the PDC-3 variant (39, 48). After two decades of chronic infection, 7 new *bla_{PDC}* allelic variants (referred to as PDC-458 to PDC-466) were identified. Each allele harbored 2 to 5 mutations relative to the ancestral *bla_{PDC-3}*, being the result of different combinations of 8 substitutions (Fig. 1C).

Substitutions G216S and V330I, which generated variant PDC-458 from the 2002 isolate were not present in the 2011 population, which instead displayed combinations of the other six substitutions distributed in six new PDC variants (Fig 1C). PDC-462 (A89V, Q120K, V213A, N321S) was the most prevalent variant in the 2011 population, being found in 14 (47%) coexisting isolates, followed by variant PDC-463 (A89V, Q120K, H189Y, V213A) that was present in 37% of the isolates. The four remaining allelic variants were rare and only present in one or two isolates (Fig. 1D).

Population dynamics of *bla_{PDC}* mutations during chronic infection

To explore the dynamics of the *bla_{PDC}* allelic prevalence in the population, a new sputum sample from patient CFD was collected in 2017, and a new set of 30 isolates was obtained. Sequencing of the *bla_{PDC}* genes from these isolates revealed a novel scenario (Fig. 2A): PDC-461 (scarcely represented in the 2011 sampling) became prevalent (being present in 39% of the isolates), overriding PDC-463 (36%). Instead, PDC-462, from being a prevalent variant was found in only 11% of the isolates. Two new *bla_{PDC}* alleles, referred to as PDC-465 and PDC-466, were observed. PDC-465 showed the same G216S substitution present in PDC-458, but combined with the novel T256P substitution. On the other hand, PDC-466 seems to derive from PDC-462 through the addition of G205D, thus

accumulating five substitutions. These two latter variants displayed a low frequency, like PDC-459, which in 2017 still maintained the low frequency observed in the 2011 population (Fig. 2A).

Overall, the main composition of *bla*_{PDC} mutations observed in 2011 was still conserved in the 2017 isolates. We wondered whether these mutations were representative of the whole population. Thus, the 2017 diversity and prevalence of *bla*_{PDC} mutations were analyzed at the population level by performing *bla*_{PDC} amplicon sequencing directly from DNA purified from whole sputum samples obtained from patient CFD (Fig. 2B).

Following coverage analysis of >5000 sequencing reads per base in the *bla*_{PDC} open reading frame, only mutations with population frequencies above 2% were considered (Table S2). A89V, Q120K, V213A, N321S were the most frequently observed substitutions, followed by H189Y and N347I (Fig. 2B). Interestingly, N347I, which was not observed in any of the isolates previously analyzed, has been reported to confer resistance to cephalosporins (39). Substitutions G216S, T256P and G205D, present in PDC-465 and PDC-466, were not detected by this sequencing analysis, probably due to the low prevalence of these variants.

This genetic analysis clearly reveals that substitutions present in the most prevalent PDC variants in either 2011 or 2017 were the most frequent substitutions observed in the global population.

Combination of multiple *bla*_{PDC} mutations generate resistance to aztreonam and cephalosporins, including ceftolozane

To dissect the role of the mutations present in the different *bla*_{PDC} allelic variants in β -lactam resistance, we designed a system to analyze resistance profiles in a common

Pseudomonas aeruginosa PAO1 genetic background that allows the control of PDC expression levels. Firstly, a *bla*_{PDC} deficient PAO1 derivative strain (PA Δ A) was constructed, in which the chromosomal *bla*_{PDC} gene was deleted. Then, the seven *bla*_{PDC} allelic variants (Fig. 1C) together with the ancestor PDC-3 variant from 1991 and the PDC-1 variant from PAO1 strain were cloned into the pMBLe vector under the control of the *lac* operator (49) and transformed into PA Δ A. The different variants expressed to similar levels, as revealed by immunodetection (Fig. S2, Table S3). Clones of PA Δ A carrying different *bla*_{PDC} alleles were challenged against a panel of anti-pseudomonal β -lactam antibiotics commonly used as therapy in CF patients (Table 1).

Bacteria expressing either PDC-3 or PDC-1 were uniformly susceptible to β -lactams, with the sole exception of piperacillin. In addition, the PDC-458 variant (from the 2002 isolate) resulted in higher resistance levels to aztreonam. In contrast, the most representative allelic variants found in the 2011 isolates (from PDC-459 to PDC-464) showed increased MICs of ceftazidime and aztreonam. These variants present different combinations of A89V, Q120K, H189Y, P154L, V213A, and N321S substitutions, resulting in triple, quadruple and quintuple substitutions. Some of these variants (PDC-459, PDC-461 and PDC-463) showed lower MICs of piperacillin and piperacillin/tazobactam, whereas none of them conferred resistance to cefepime or the carbapenems imipenem and meropenem (Table 1). All variants harboring the Q120K substitution (PDC-459, -461 to -464) showed high resistance levels to ceftolozane ($S \leq 4$ μ g/mL), either alone or combined with the β -lactamase inhibitor tazobactam ($S \leq 4/2$ μ g/mL) (Table 1). These results show that ceftolozane resistance is due (at least partially) to these substitutions in PDC. The highest resistance to both ceftazidime and ceftolozane was conferred by the PDC-459 combination, Q120K, P154L and V213A followed by PDC-461, which clusters A89V, Q120K and V213A. Additions of N321S and H189Y to

the latter triple-mutation combination in PDC-462 and PDC-463, respectively, not only increased resistance to aztreonam but also reverted the decrease in piperacillin resistance observed in PDC-461 (Table 1).

Differential competitiveness of coexisting-PDC variants can shape the dynamics of resistant subpopulation of *P. aeruginosa* upon exposure to β -lactams

The effect of multiple combined *bla*_{PDC} mutations on bacterial fitness was explored by performing competitive growth assays using the *P. aeruginosa* PA $\Delta\Delta$ strain carrying *bla*_{PDC} allelic most prevalent variants among CFD 2011 and 2017 populations (referred to as PA $\Delta\Delta$ -461, PA $\Delta\Delta$ -462, PA $\Delta\Delta$ -463, and PA $\Delta\Delta$ -464), tagged with the *lacZ* gene. These allelic variants combined A89V, Q120K, H189Y, V213A and N321S substitution to generate triple, quadruple or quintuple variant PDCs (Fig. 1C and 2). Pairs of tagged/untagged strains were co-cultured *in vitro* and then plated on LB-agar plates containing X-gal.

We first evaluated the relative fitness by competing each variant with the PA $\Delta\Delta$ strain expressing the ancestral PDC-3 variant (PA $\Delta\Delta$ -3). As shown in Fig. 3A and B, significant differences were not observed in the absence of antibiotics. Instead, in the presence of the β -lactams ceftazidime or aztreonam (the antibiotics used in the therapy of patient CFD), PA $\Delta\Delta$ -461, PA $\Delta\Delta$ -462, PA $\Delta\Delta$ -463, and PA $\Delta\Delta$ -464 clearly outcompeted PA $\Delta\Delta$ -0. PA $\Delta\Delta$ -464 showed lower levels of competitiveness than PA $\Delta\Delta$ -461, PA $\Delta\Delta$ -462 and PA $\Delta\Delta$ -463, indicating that the introduction of a fifth substitution can compromise resistance to these antibiotics.

When competed between each other upon ceftazidime exposure, PA $\Delta\Delta$ -461 showed a clear advantage over PA $\Delta\Delta$ -462, -463 and -464 (Fig. 3C), suggesting that the A89V/Q120K/V213A combination reached the highest relative fitness, whereas

additional substitutions impaired competitiveness in the presence of this antibiotic. For instance, the quadruple variant PA Δ A-462 showed higher fitness than PA Δ A-463 (harboring H189Y instead of N321S) and PA Δ A-464 (harboring both, H189Y and N321S), which in turn outcompeted PA Δ A-463 (Fig. 3C).

In the presence of aztreonam, a clear fitness advantage was observed for all variants against PA Δ A-464. Yet, PA Δ A-463 and PA Δ A-462 showed higher relative fitness than PA Δ A-461, suggesting that the addition of N321S and H189Y extend the spectrum of β -lactam resistance (Fig. 3D).

These results support that the high prevalence of PDC-462 and PDC-463 variants in the 2011 population are correlated with the simultaneous administration of ceftazidime and aztreonam that took place prior to sample collection (Fig.s 1A and D). Subsequently, the repeated rounds of ceftazidime treatments have clearly shaped the 2017 population, where PDC-461, the most resistant variant against cephalosporins, prevailed (Fig. 2A).

PDC variants show improved hydrolytic activity toward ceftazidime and ceftolozane

We next assessed the capacity of the most relevant PDC variants to hydrolyze β -lactams. The mature PDC-3, PDC-461, PDC-462 and PDC-463 proteins were expressed and purified from *E. coli* cultures to homogeneity. Then, we performed steady-state kinetic measurements to test the catalytic efficiencies against the β -lactams ceftazidime, piperacillin and imipenem. In agreement with previous reports (44, 48, 50), PDC-3 hydrolyzed efficiently piperacillin while showing a poor hydrolytic activity against ceftazidime, ceftolozane and imipenem (Table 2).

PDC-461, -462 and -463 efficiently hydrolyzed ceftazidime, showing 28-, 29- and 13- increased catalytic efficiencies (respectively) relative to the ancestor PDC-3, indicating that mutations in these PDC improved their catalytic performance on this

cephalosporin. PDC-461 displayed a catalytic efficiency against piperacillin 100-fold impaired with respect to PDC-3, disclosing a tradeoff in the substrate profile shaped by the presence of the three core mutations (A89V, Q120K and V213A). Instead, the additional mutations present in PDC-462 and PDC-463 were able to restore this activity. Indeed, PDC-462 displayed hydrolytic levels against piperacillin similar to PDC-3, in agreement with the observed piperacillin MICs for the strain expressing this variant (Table 1).

All PDC variants maintained low hydrolysis rates for imipenem, displaying k_{cat} values between 0.01 and 0.04 s⁻¹, which correlate well with the imipenem susceptibility (MICs of 1 to 2 µg/mL) observed in PAΔA expressing either PDC-461, -462 or -463 variants (Table 1). Remarkably, when the catalytic efficiencies of PDC-461, -462 and -463 were assessed against the recently introduced cephalosporin ceftolozane, the k_{cat}/K_m ratios showed significantly increased values compared to that of the parental enzyme. PDC-462 and 463 show 16- and 8-fold enhancements of this activity, a performance that is largely overcome by PDC-461, showing a 150-fold increase in k_{cat}/K_m .

These catalytic efficiencies correlate very well with the MIC levels of different antibiotics determined in an isogenic *Pseudomonas* background (Table 1), revealing that the different accumulated mutations are responsible of tuning the substrate profile of these variants.

Molecular dynamics simulations reveal enlargement of substrate-binding pocket in PDC evolved mutants

The different substitutions present in the studied variants are scattered in the protein structure, many of them being part of protein loops (Fig. 4). Expansion of the substrate profile by mutations in β-lactamases has been accounted for by changes in the protein

dynamics. Therefore, we performed classical molecular dynamics (MD) simulations on these variants (PDC-3, PDC-461, PDC-462, and PDC-463) in the unbound state. MD simulations were run for 200 ns and conformational clustering was performed as described (51-53). All proteins preserved their global tertiary structure during the MD simulations but revealed significant changes in the substrate binding pocket elicited by the substitutions (Fig. 5).

The three variants showing an enhanced activity towards ceftazidime and ceftolozane (PDC-461, PDC-462, and PDC-463) present a broader active site cavity (Fig. S3). Substitution V213A induces a conformational change in the Ω -loop, involving residues 200-223. As a result, a hydrogen bond formed by phenolic OH of Y223 with the backbone of G214 present in PDC-3 is lost, inducing a conformational change in Y223 in PDC-461. Mutation Q120K eliminates a hydrogen bonding interaction of the amide side chain with N153 (from the YSN loop, located in the opposite side of the substrate binding pocket). This results in a conformational change of this residue, with Lys120 pointing outwards and therefore further widening the active site cavity (Fig. 6). The structural impact of this mutation is similar in PDC-461, -462 and -463, i.e., regardless the genetic background, highlighting the key role of the Q120K mutation in the evolution of resistance.

Representative conformations extracted from the MD simulations were used to build *in silico* the complexes of each PDC variant with ceftazidime, using the crystal structure of acylated ceftazidime bound to EDC (*Escherichia coli*-derived cephalosporinase) (PDB 1IEL) (54) as a template. In order to understand the interaction of ceftazidime with the protein environment, we optimized these structures by hybrid quantum mechanics-molecular mechanics (QM-MM) simulations. In all four complexes, ceftazidime interacts with residues S64, K67, N153, Y223, S319, N321, N344, and N347,

in agreement with the previous structural information (44, 54). The active site changes in the mutants allows a better accommodation of the bulky R1 side chain from ceftazidime (Fig.s 5B and S3). In addition, the conformational change of Y223 results in an aromatic stacking interaction with the 4-thiazolyl ring of ceftazidime (Fig. S4) at the R1 substituent. The N321S substitution in PDC-462 removes a hydrogen bond with A213 at the Ω -loop that enables to recover the interaction between Y223 and G214. Overall, all variants show a broadening of the active site that accounts for the large increase in activity and resistance against ceftazidime of these PDC variants.

DISCUSSION

Laboratory-based experimental evolution experiments have been extensively used to replicate bacterial adaptation during antibiotic therapy (2, 5-7, 37, 55, 56). This approach reduces complexity in order to establish reproducible and well-controlled conditions, from which evolutionary changes and mutational trajectories can be analyzed. However, it has become increasingly clear that *in vitro* antibiotic selection experiments do not necessarily replicate resistance development taking place in more complex settings, where many variables and selective factors can influence the adaptive potential and outcome in bacterial populations (57, 58). Exploring long-term evolution in ‘natural’ environments, such as those from within-host populations, allows one to embrace this complexity, providing new information that can be relevant for the development of novel strategies to control and/or prevent antibiotic resistance during infections.

A previous study of the evolution of *P. aeruginosa* hypermutator lineages combining longitudinal and cross-sectional analysis covering decades of CF chronic infection showed that antibiotic resistance increases as infection progresses towards the establishment of a highly diversified population, that converges towards multidrug resistance (25, 47). Here we have dissected the specific effects of mutations accumulated in the β -lactamase *ampC* gene (*bla_{PDC}*) in isolates from a single patient who received a long-term treatment (26 years) with β -lactam antibiotics. Importantly, the adaptive evolution of PDC resulted from an accumulation of multiple mutations in the *bla_{PDC}* gene that, when combined, resulted in high level β -lactam resistance. In particular, we show a large increase in the hydrolytic capability of variants PDC-461, PDC-462 and PDC-463 against ceftazidime and ceftolozane, providing a structural and functional rationale, and analyze these findings in the framework of the complexity of the bacterial population elicited by a hypermutator strain.

The concept of population phenotype is related to the frequencies and distribution of relevant alleles in bacterial populations, which can shape community functions and influence clinical outcomes (59). In this work, we demonstrate how the dynamics of multiple and changing antibiotic pressures, together with higher mutation rates, resulted in high allelic variations of the PDC β -lactamase in a diversified resistant clonal population that originally evolved from a susceptible ancestral infecting strain. Noteworthy, the many coexisting PDC variants, each conferring particular spectrum resistance profiles, provide a wider β -lactam resistant phenotype to the population as a whole. For example, one of the most prevalent variants, PDC-461 confers the highest resistance to cephalosporins in an activity trade-off that causes collateral sensitivity to piperacillin. During subsequent steps along therapy, PDC-462 and PDC-463 have acquired insertions of novel “gain-of-function” substitutions in the PDC-461 background, which result in a wider substrate spectrum maintaining cephalosporin resistance, with higher resistance to aztreonam, and restored resistance to piperacillin.

The high efficiency acquired by these PDC variants to confer resistance to the novel anti-pseudomonal cephalosporin, ceftolozane, is of great interest. To the end of our knowledge, this is the first study describing collateral resistance to ceftolozane in a patient that has never been treated with this antibiotic. Resistance to ceftolozane has previously been observed in *P. aeruginosa* infected patients when treated with this antibiotic (40, 60), and other studies have demonstrated that expression of a PDC-3 variant carrying a single E221K mutation can confer high MICs of ceftolozane in *E. coli* (44). It has also been shown that a substitution of Asp219 at the Ω -loop 219, selected after treating a multi-drug resistant *P. aeruginosa* strain with ceftolozane/tazobactam, enhances hydrolysis of this cephalosporin/ β -lactamase inhibitor combination *in vivo* (45). However, *in vitro* long-term experiments of wild-type and mutator strains of *P. aeruginosa* exposed to

increasing concentrations of ceftolozane/tazobactam, showed that only mutator strains were able to develop high-levels of resistance, by acquiring multiple mutations that led to overexpression and structural modifications of PDC (37). The value of an increased mutational and innovative potential caused by hypermutability is documented in our *in-patient* study, making it understandable why hypermutators are frequently isolated from bacterial populations challenged by stressful conditions over long time periods (17, 61, 62).

In addition to diverse polymorphisms previously described for PDC, we report three new amino acid substitutions: A89Y, G205D and T256P, which together with Q120K, P154L, H189Y, V213A, G216S, N321S, V330I and N347I mutations generated novel *bla*_{PDC} allelic variants, each harboring from 2 to 5 mutations. P154L, V213A, and N347I are located next to the conserved YSN loop, the C-terminal region of Ω -loop and the C3/C4 recognition region, respectively, and have been shown to individually confer resistance to β -lactam antibiotics in *P. aeruginosa* clinical isolates (39, 44). The finding of new combinations that further boost cephalosporin resistance supports the adaptability of the PDC scaffold to tolerate various mutations, which at the same time provides a substantial gain-of-function.

The three most prevalent alleles are those that combine mutations A89V, Q120K and V213A and, at the same time, confer the highest resistance to cephalosporins and enhanced competitiveness in the presence of ceftazidime. Molecular dynamics simulations revealed that these three mutations give rise to a wider substrate-binding pocket in the PDC variants. This change favors binding of ceftazidime to the active site, providing space for better accommodating the R1 side chain of this antibiotic (Fig. S5). In addition, substitutions Q120K and V213A trigger a different orientation in the aromatic group of Y223 in the PDC-461 variant, favoring a stacking interaction with the 4-thiazolyl

ring present in the R1 group. Other substitutions located in or near the Ω -loop have been shown to enhance cephalosporin resistance by altering the conformation of Y223 (44, 54, 63). This conformational change improves hydrolysis of ceftazidime, ceftolozane and aztreonam, but has the opposite effect on piperacillin. Instead, the N321S substitution in variant PDC-462 restores the Y223 orientation present in PDC-3 while maintaining the enlargement of the substrate-binding pocket, thus extending the hydrolysis towards ceftazidime, ceftolozane, aztreonam and piperacillin. These results suggest that the broadening of the active site induced by the different mutations is more relevant than the interaction with Y223.

The Q120K mutation results in a net widening of the active site entrance, due to the conformational change of the side chain (Fig. 6). The impact of Q120K in resistance is evident from analyzing PDC-462 and PDC-460, which differ only by this substitution. The presence of this substitution elicits an impressive increase by 3-fold dilutions in the MICs towards ceftazidime, aztreonam, and ceftolozane (Table 1). We conclude that Q120K plays an important role in the evolution of resistance in this family of variants.

These structural changes result in a better accommodation of the R1 group from ceftazidime: the volume in the active site region that recognizes R1 is increased by more than two-fold in PDC-461, PDC-462 and PDC-463 compared to PDC-3. Interestingly, the R1 group structure, which has been associated with the antipseudomonal activity (64), is almost identical in aztreonam, ceftazidime, and ceftolozane (Fig. S5). In contrast, changes in the volume of the active site cleft where R2 is located are not perceived to be important for the binding of ceftazidime. We conclude, that optimization of R1 binding driven by ceftazidime circumvents this problem and provides a better recognition of both aztreonam and ceftolozane. In the report by Berrazeg and coworkers (39), the authors proposed that either ceftazidime or cefepime could induce this effect. In light of the

current study, we conclude that it is unlikely that cefepime could elicit a similar cross-resistance effect as ceftazidime since the R1 group is different in this antibiotic.

In conclusion, our detailed analysis of a *P. aeruginosa* clone persisting within a single patient reveals how the outcome of decades of evolution driven by consistent and intensive antibiotic treatment in the setting of a hypermutator genotype leads to a multidrug resistance phenotype, primarily driven by combined substitutions in the chromosomal β -lactamase, PDC. The amazing plasticity of the PDC structure not only confirms the already known capacity to evolve when facing the challenge of new β -lactams, but also warns us that chemical similarities among β -lactams from different generations could lead to an unexpected evolution of resistance, particularly in the context of a chronic infection by a hypermutator strain. This work emphasizes the huge evolutionary potential of hypermutator strains and uncovers the link between the antibiotic prescription history and the *in-patient* evolution of antibiotic resistance that relies on a molecular-based hypothesis of the adaptation of the PDC β -lactamase.

MATERIALS AND METHODS

Clinical isolates were obtained from sputum samples from an adult patient with cystic fibrosis attending the Copenhagen Cystic Fibrosis Center at University Hospital Rigshospitalet, Denmark (CFD Patient) (25). The use of the samples was approved by the local ethics committee of the Capital Region of Denmark (Region Hovedstaden; registration numbers H-A-141 and H-1-2013-032), and patient gave informed consent.

Isolation and identification of *P. aeruginosa* from sputum was carried out as previously described (65). Patient age at the time of the first isolate collection was 23 years and the onset of the chronic infection with *P. aeruginosa* was in 1986. The *P. aeruginosa* collection included: an initial isolate from 1991, two intermediate isolates from 1995 and

2002, and two populations of isolates collected in 2011 (25) and 2017 (this study). For cross-sectional analysis, 30 isolates were taken randomly from the 2011 and 2017 sputum samples. Isolates were stored at -70°C in glycerol stock solution. The 2017 sputum sample was divided in two: one for the isolation of *P. aeruginosa* clones and the other for DNA extraction for ultra-deep sequencing analysis.

The sequences of the *bla*_{PDC} gene corresponding to the described PDCs variants have been deposited in GenBank under the accession numbers shown in SI Appendix.

Materials and methods describing the sequence analysis of *bla*_{PDC} gene in *P. aeruginosa* CFD isolates, DNA extraction and PCR amplification of *bla*_{PDC} gene from whole sputum samples; the construction of *P. aeruginosa* Δ *bla*_{PDC} deficient (PA Δ A) and *bla*_{PDC}-*lacZ* (PA Δ A-*lacZ*) strains; cloning of *bla*_{PDC} allelic variants and expression levels of PDCs in pMBLe vector; competition experiments for determination of competitive fitness of *bla*_{PDC} variants; expression and purification of PDC proteins; classical molecular dynamic simulations and QM-MM calculations with the PDC variants (in apo versions) and PDC in complex with ceftazidime are described in detail in the SI Appendix section Materials and Methods.

ACKNOWLEDGEMENTS

AMS thanks ANPCyT (PICT-2016-1545 and PICT-2019-1590, SECYT, UNC (grant 33620180100413CB, MINCyT-Córdoba (PID-2018-Res. 144) for funding. AJV thanks ANPCyT (PICT-2016-1657) and NIH (R01AI100560) for funding. PET thanks ANPCyT (PICT-2019-1358) for funding. AAO thanks ANPCyT (PICT-2016-1926) for funding. AMS, AJV, PET, AAO and AJM are staff members from CONICET. CAC, GD and LGH are recipients of fellowships from CONICET. The Novo Nordisk Foundation supported HKJ as a clinical research stipend (grant NNF12OC1015920). Rigshospitalet

Rammebevilling 2015-17 (R88-A3537), Lundbeckfonden (R167-2013-15229), Det Frie Forskningsråd FSS (DFF-4183-00051), RegionH rammebevilling (R144-A5287), The Novo Nordisk Foundation (NNF15OC0017444 and NNF18OC0052776) and Savværksejer Jeppe Juhl og Hustru Ovita Juhls Memorial Fund supported HKJ. National Institute of Allergy and Infectious Diseases of NIH supported RAB (R01AI100560, R01AI063517, and R01AI072219). A grant was also provided by Merck & Co., Inc., Kenilworth, NJ USA to RAB. The Cleveland Department of Veterans Affairs (1I01BX001974) supported RAB from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development, and the Geriatric Research Education and Clinical Center VISN 10. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Department of Veterans Affairs.

AUTHOR CONTRIBUTION

AMS and AJV designed research and supervised the study. CAC, PET, AGAO, GD, RAH, LGH, SF, AJM performed experimental research. HKJ provided clinical samples and bacterial collection. CAC and LMSM analyzed bioinformatics ultra-deep sequencing data. DMM, performed molecular modeling analyses. CAC, PET, AGAO, DMM, RAB, HKJ, SM, AJV and AMS analyzed data; RAB, SM, AJV and ASM wrote the paper.

COMPETING INTERESTS

Authors declare no competing interests

REFERENCES

1. Weinreich DM, Delaney NF, DePristo MA, & Hartl DL (2006) Darwinian Evolution Can Follow Only Very Few Mutational Paths to Fitter Proteins. *Science (New York, N.Y.)* 312(5770):111-114.
2. Card KJ, Thomas MD, Graves JL, Barrick JE, & Lenski RE (2021) Genomic evolution of antibiotic resistance is contingent on genetic background following a long-term experiment with *Escherichia coli*. *Proceedings of the National Academy of Sciences* 118(5):e2016886118.
3. Boolchandani M, D'Souza AW, & Dantas G (2019) Sequencing-based methods and resources to study antimicrobial resistance. *Nature Reviews Genetics* 20(6):356-370.
4. Elena SF & Lenski RE (2003) Evolution experiments with microorganisms: the dynamics and genetic bases of adaptation. *Nature Reviews Genetics* 4(6):457-469.
5. Baym M, Stone LK, & Kishony R (2016) Multidrug evolutionary strategies to reverse antibiotic resistance. *Science (New York, N.Y.)* 351(6268):aad3292.
6. Palmer AC & Kishony R (2013) Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. *Nat Rev Genet* 14(4):243-248.
7. MacLean RC, Hall AR, Perron GG, & Buckling A (2010) The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. *Nature Reviews Genetics* 11(6):405-414.
8. Mehlhoff JD, *et al.* (2020) Collateral fitness effects of mutations. *Proceedings of the National Academy of Sciences* 117(21):11597-11607.

9. Bershtein S, Segal M, Bekerman R, Tokuriki N, & Tawfik DS (2006) Robustness–epistasis link shapes the fitness landscape of a randomly drifting protein. *Nature* 444(7121):929-932.
10. Meini M-R, Tomatis PE, Weinreich DM, & Vila AJ (2015) Quantitative Description of a Protein Fitness Landscape Based on Molecular Features. *Molecular biology and evolution* 32(7):1774-1787.
11. Stiffler Michael A, Hekstra Doeke R, & Ranganathan R (2015) Evolvability as a Function of Purifying Selection in TEM-1 β -Lactamase. *Cell* 160(5):882-892.
12. Andersson DI, *et al.* (2020) Antibiotic resistance: turning evolutionary principles into clinical reality. *FEMS Microbiology Reviews* 44(2):171-188.
13. Frimodt-Møller J, *et al.* (2018) Mutations causing low level antibiotic resistance ensure bacterial survival in antibiotic-treated hosts. *Sci Rep* 8(1):12512.
14. Prickett MH, *et al.* (2017) Aminoglycoside resistance of *Pseudomonas aeruginosa* in cystic fibrosis results from convergent evolution in the *mexZ* gene. *Thorax* 72(1):40-47.
15. Lister PD, Wolter DJ, & Hanson ND (2009) Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev* 22(4):582-610.
16. Cabot G, *et al.* (2012) Genetic markers of widespread extensively drug-resistant *Pseudomonas aeruginosa* high-risk clones. *Antimicrobial agents and chemotherapy* 56(12):6349-6357.
17. Oliver A, Canton R, Campo P, Baquero F, & Blazquez J (2000) High frequency of hypermutable *Pseudomonas aeruginosa* in cystic fibrosis lung infection. *Science (New York, N.Y.)* 288(5469):1251-1254.

18. Ciofu O, Riis B, Pressler T, Poulsen HE, & Hoiby N (2005) Occurrence of hypermutable *Pseudomonas aeruginosa* in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. *Antimicrobial agents and chemotherapy* 49(6):2276-2282.
19. Macia MD, *et al.* (2005) Hypermutation is a key factor in development of multiple-antimicrobial resistance in *Pseudomonas aeruginosa* strains causing chronic lung infections. *Antimicrobial agents and chemotherapy* 49(8):3382-3386.
20. Montanari S, *et al.* (2007) Biological cost of hypermutation in *Pseudomonas aeruginosa* strains from patients with cystic fibrosis. *Microbiology (Reading, England)* 153(Pt 5):1445-1454.
21. Mena A, *et al.* (2008) Genetic adaptation of *Pseudomonas aeruginosa* to the airways of cystic fibrosis patients is catalyzed by hypermutation. *Journal of bacteriology* 190(24):7910-7917.
22. Moyano AJ, Lujan AM, Argarana CE, & Smania AM (2007) MutS deficiency and activity of the error-prone DNA polymerase IV are crucial for determining *mucA* as the main target for mucoid conversion in *Pseudomonas aeruginosa*. *Molecular microbiology* 64(2):547-559.
23. Lujan AM, Moyano AJ, Segura I, Argarana CE, & Smania AM (2007) Quorum-sensing-deficient (*lasR*) mutants emerge at high frequency from a *Pseudomonas aeruginosa mutS* strain. *Microbiology (Reading, England)* 153(Pt 1):225-237.
24. Feliziani S, *et al.* (2010) Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in *Pseudomonas aeruginosa* from cystic fibrosis chronic airways infections. *PLOS ONE* 5(9):e12669.

25. Feliziani S, *et al.* (2014) Coexistence and within-host evolution of diversified lineages of hypermutable *Pseudomonas aeruginosa* in long-term cystic fibrosis infections. *PLOS Genetics* 10(10):e1004651.
26. Marvig RL, Johansen HK, Molin S, & Jelsbak L (2013) Genome analysis of a transmissible lineage of *Pseudomonas aeruginosa* reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. *PLOS Genetics* 9(9):e1003741.
27. Luján AM, *et al.* (2011) Evolution and adaptation in *Pseudomonas aeruginosa* biofilms driven by mismatch repair system-deficient mutators. *PLOS ONE* 6(11):e27842.
28. Folkesson A, *et al.* (2012) Adaptation of *Pseudomonas aeruginosa* to the cystic fibrosis airway: an evolutionary perspective. *Nature Reviews Microbiology* 10(12):841-851.
29. Breidenstein EB, de la Fuente-Nunez C, & Hancock RE (2011) *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends in microbiology* 19(8):419-426.
30. Moya B, *et al.* (2009) Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. *PLoS pathogens* 5(3):e1000353.
31. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, & Martínez JL (2010) Genetic determinants involved in the susceptibility of *Pseudomonas aeruginosa* to β -lactam antibiotics. *Antimicrobial agents and chemotherapy* 54(10):4159-4167.
32. Fisher JF & Mobashery S (2014) The sentinel role of peptidoglycan recycling in the beta-lactam resistance of the gram-negative *Enterobacteriaceae* and *Pseudomonas aeruginosa*. *Bioorganic chemistry* 56:41-48.

33. Tsutsumi Y, Tomita H, & Tanimoto K (2013) Identification of novel genes responsible for overexpression of *ampC* in *Pseudomonas aeruginosa* PAO1. *Antimicrobial agents and chemotherapy* 57(12):5987-5993.
34. Calvopiña K & Avison MB (2018) Disruption of *mpl* Activates β -Lactamase Production in *Stenotrophomonas maltophilia* and *Pseudomonas aeruginosa* Clinical Isolates. *Antimicrobial agents and chemotherapy* 62(8):e00638-00618.
35. Rodriguez-Martinez JM, Poirel L, & Nordmann P (2009) Molecular epidemiology and mechanisms of carbapenem resistance in *Pseudomonas aeruginosa*. *Antimicrobial agents and chemotherapy* 53(11):4783-4788.
36. Lahiri SD, *et al.* (2014) Avibactam and class C beta-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. *Antimicrobial agents and chemotherapy* 58(10):5704-5713.
37. Cabot G, *et al.* (2014) *Pseudomonas aeruginosa* ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. *Antimicrobial agents and chemotherapy* 58(6):3091-3099.
38. Lahiri SD, *et al.* (2015) Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in *Pseudomonas aeruginosa* strains containing derepressed AmpC. *The Journal of antimicrobial chemotherapy* 70(6):1650-1658.
39. Berrazeg M, *et al.* (2015) Mutations in beta-lactamase AmpC increase resistance of *Pseudomonas aeruginosa* isolates to antipseudomonal cephalosporins. *Antimicrobial agents and chemotherapy* 59(10):6248-6255.
40. Fraile-Ribot PA, *et al.* (2018) Mechanisms leading to *in vivo* ceftolozane/tazobactam resistance development during the treatment of infections

- caused by MDR *Pseudomonas aeruginosa*. *The Journal of antimicrobial chemotherapy* 73(3):658-663.
41. MacVane SH, Pandey R, Steed LL, Kreiswirth BN, & Chen L (2017) Emergence of ceftolozane-tazobactam-resistant *Pseudomonas aeruginosa* during treatment is mediated by a single AmpC structural mutation. *Antimicrobial agents and chemotherapy* 61(12).
 42. Oliver A (2020) Antibiotic Resistance and Pathogenicity of Bacterial Infections Group - IdISBa
 43. Raimondi A, Sisto F, & Nikaido H (2001) Mutation in *Serratia marcescens* AmpC β -Lactamase Producing High-Level Resistance to Ceftazidime and Cefpirome. *Antimicrobial agents and chemotherapy* 45(8):2331-2339.
 44. Barnes MD, *et al.* (2018) Deciphering the evolution of cephalosporin resistance to ceftolozane-tazobactam in *Pseudomonas aeruginosa*. *mBio* 9(6):e02085-02018.
 45. Arca-Suárez J, *et al.* (2020) Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR *Pseudomonas aeruginosa* infection. *The Journal of antimicrobial chemotherapy*.
 46. Jacoby GA (2009) AmpC β -lactamases. *Clin Microbiol Rev* 22(1):161-182.
 47. Colque CA, *et al.* (2020) Hypermutator *Pseudomonas aeruginosa* exploits multiple genetic pathways to develop multidrug resistance during long-term infections in the airways of cystic fibrosis patients. *Antimicrobial agents and chemotherapy*:AAC.02142-02119.

48. Rodríguez-Martínez J-M, Poirel L, & Nordmann P (2009) Extended-Spectrum Cephalosporinases in *Pseudomonas aeruginosa*. *Antimicrobial agents and chemotherapy* 53(5):1766-1771.
49. González LJ, *et al.* (2016) Membrane anchoring stabilizes and favors secretion of New Delhi metallo- β -lactamase. *Nat Chem Biol* 12(7):516-522.
50. Drawz SM, Taracila M, Caselli E, Prati F, & Bonomo RA (2011) Exploring sequence requirements for C₃/C₄ carboxylate recognition in the *Pseudomonas aeruginosa* cephalosporinase: Insights into plasticity of the AmpC β -lactamase. *Protein Sci* 20(6):941-958.
51. González LJ, Stival C, Puzzolo JL, Moreno DM, & Vila AJ (2018) Shaping Substrate Selectivity in a Broad-Spectrum Metallo- β -Lactamase. *Antimicrobial agents and chemotherapy* 62(4):e02079-02017.
52. González LJ, Moreno DM, Bonomo RA, & Vila AJ (2014) Host-Specific Enzyme-Substrate Interactions in SPM-1 Metallo- β -Lactamase Are Modulated by Second Sphere Residues. *PLoS pathogens* 10(1):e1003817.
53. Morán-Barrio J, *et al.* (2016) Crystal Structure of the Metallo- β -Lactamase GOB in the Periplasmic Dizinc Form Reveals an Unusual Metal Site. *Antimicrobial agents and chemotherapy* 60(10):6013-6022.
54. Powers RA, Caselli E, Focia PJ, Prati F, & Shoichet BK (2001) Structures of Ceftazidime and Its Transition-State Analogue in Complex with AmpC β -Lactamase: Implications for Resistance Mutations and Inhibitor Design. *Biochemistry* 40(31):9207-9214.
55. Card KJ, LaBar T, Gomez JB, & Lenski RE (2019) Historical contingency in the evolution of antibiotic resistance after decades of relaxed selection. *PLOS Biology* 17(10):e3000397.

56. Windels EM, Van den Bergh B, & Michiels J (2020) Bacteria under antibiotic attack: Different strategies for evolutionary adaptation. *PLoS pathogens* 16(5):e1008431.
57. Baker S, Thomson N, Weill F-X, & Holt KE (2018) Genomic insights into the emergence and spread of antimicrobial-resistant bacterial pathogens. *Science (New York, N.Y.)* 360(6390):733-738.
58. Didelot X, Walker AS, Peto TE, Crook DW, & Wilson DJ (2016) Within-host evolution of bacterial pathogens. *Nature Reviews Microbiology* 14(3):150-162.
59. Azimi S, *et al.* (2020) Allelic polymorphism shapes community function in evolving *Pseudomonas aeruginosa* populations. *The ISME Journal* 14(8):1929-1942.
60. Munita JM, *et al.* (2017) Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant *Pseudomonas aeruginosa*. *Clinical Infectious Diseases* 65(1):158-161.
61. Matic I (2019) Mutation Rate Heterogeneity Increases Odds of Survival in Unpredictable Environments. *Molecular Cell* 75(3):421-425.
62. Denamur E & Matic I (2006) Evolution of mutation rates in bacteria. *Molecular microbiology* 60(4):820-827.
63. Thomas VL, McReynolds AC, & Shoichet BK (2010) Structural Bases for Stability–Function Tradeoffs in Antibiotic Resistance. *Journal of Molecular Biology* 396(1):47-59.
64. Zasowski EJ, Rybak JM, & Rybak MJ (2015) The β -Lactams Strike Back: Ceftazidime-Avibactam. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* 35(8):755-770.

65. Høiby N & Frederiksen B (2000) Microbiology of cystic fibrosis. *Cystic Fibrosis*, (Arnold Publishers - International book and journal publishers London), pp 83-107.
66. Mack AR, *et al.* (2020) A Standard Numbering Scheme for Class C β -Lactamases. *Antimicrobial agents and chemotherapy* 64(3):e01841-01819.

FIGURES & TABLES




Fig. 1. β -lactamase PDC variants from CFD isolates. A) Overview of isolate sampling time points and β -lactam antibiotic treatment throughout the 26-years study. *P. aeruginosa* isolates were collected from patient CFD between 1991 and 2017. Dotted lines indicate the time of isolation of the 1991, 1995, and 2002 isolates, as well as the collections of 30 isolates from single sputum samples in 2011 and 2017. The plus and minus symbols indicate the hypermutability state of the *P. aeruginosa* strains. The β -lactam antibiotics used in chemotherapy are listed on the y axis. Treatment with this group of antibiotics started from 1986 and lasted until end of 2016. Gray circles indicate the start and end of an antibiotic dose. B) Clustering of CFD isolates sequenced in Feliziani *et al.* (25), based on maximum-parsimony analysis. Circle colors represent different types of PDC variants from CFD isolates. C) Schematic representation of the β -lactamase PDC

protein sequence strain PAO1, and of the 8 PDC-variants that emerged during the 20 years of evolution, with their amino acid variations respect to PAO1. Numbering of amino acids refers to the mature protein of PAO1 strain, after cleavage of the 26 N-terminal amino acid residues from the signal peptide, according to the PDC-wide structural position system (SANAC numbering) (66). Early isolates from 1991 and 1995 harbor PDC-3 with a T79A polymorphism, which was also present in all the sequenced isolates. Isolate from 2002 harbored PDC-458 variant. The set of 30 isolates evaluated in 2011 harbored PDC-459 to PDC-464 variants. D) Pie chart indicates the percentage of each PDC variant in the 2011 population, respect to the total number of isolates (30) in which *bla_{PDC}* gene was sequenced. PDC-3 differs from PDC-1 from PAO1 by the T79A mutation, which does not affect resistance nor the substrate specificity of the lactamase (39, 48).




Fig. 2. Population analysis on CFD 2017 sample. Sputum sample collected from patient CFD was divided in two and each half was processed for A) Sanger sequencing of *bla*_{PDC} gene in 30 isolates for which sputa was plated in *Pseudomonas* isolation agar and grown for 48hs at 37°C. Pie chart indicates the percentage of each PDC variant in the 2017 population, respect to the total number of isolates sequenced. B) Sequencing of *bla*_{PDC} gene directly amplified on sputum sample for which DNA was extracted and sequenced on Illumina MiSeq. Graph represent the percentage of total reads of each amino acid (AA) variation in the whole population of *P. aeruginosa* (Table S2). T79A (grey bar), considered as a polymorphism that does not affect β -lactam resistance (39), was in the 100% of the population confirming CFD patient was colonized by a *P. aeruginosa* lineage derived by a single ancestral clone containing the PDC-3 variant.




Fig. 3. *In vitro* competition experiments among different *bla*_{PDC} alleles. Competition experiments were performed in the absence or presence of ceftazidime (CAZ, A and C) or aztreonam (AZT, B and D). *PAΔA* strain expressing PDC-461, PDC-462, PDC-463 or PDC-464 (i.e. *PAΔA*-461, *PAΔA*-462, *PAΔA*-463, and *PAΔA*-464) were competed against *PAΔA* expressing PDC-3 (*PAΔA*-3). Fitness (S) relative to *PAΔA*-3 for (A) ceftazidime or (B) aztreonam are shown. Then, *PAΔA*-461, *PAΔA*-462, *PAΔA*-463 and *PAΔA*-464 were competed against each other in the absence of antibiotics or presence of (C) ceftazidime or (D) aztreonam. (See SI Appendix for scheme of antibiotic concentration). Measurements were carried out in triplicates for at least two independent experiments, and the results are expressed as means with their SEM. Statistically significant differences at $p < 0.0001$, $p < 0.01$ and $p < 0.05$ are identified by ****, ** and *, respectively (two-way ANOVA followed by Tukey's Multiple Comparisons Test).




Fig. 4. Representation of the PDC β -lactamase structure from *P. aeruginosa* PAO1 (PDB 4OOY doi:10.2210/PDB4OOY/PDB). The different structural regions lining the binding site are colored as follows: omega loop, red; helix H-10, blue; R2 loop, orange; and YSN, purple. The amino acids residues which were mutated across the different *bla_{PDC}* allelic variants in this study are represented with sticks in green and pointed with arrows.




Fig. 5. Molecular modeling of PDC proteins. Structures of the apo/free versions (A) and coupled with ceftazidime antibiotic CAZ (B) with their active site cavities are shown. Colors of protein structures: PDC-3 (grey), PDC-461 (yellow), PDC-462 (purple) and PDC-463 (green).




Fig. 6. Comparison of representative snapshots of the MD simulations of each protein studied vs PDC-3 showing the active site cavity environment (R1 region). In all representations, N atoms are depicted in blue, oxygen atom in red and key residues are highlighted in sticks. C atoms of the PDC-3 are depicted in grey. A) PDC-3 vs PDC-461

(C atoms in yellow) B) PDC-3 vs PDC-462 (C atoms in purple) C) PDC-3 vs PDC-463
(C atoms in green). Residue distances are depicted with dashed lines.

Table 1. Susceptibility profiles of PA $\Delta\Delta$ strain complemented with the different PDC variants.

Strains ^a	MIC ($\mu\text{g/mL}$) ^b								
	CAZ S; ≤ 8	CTZ S; ≤ 4	CTZ/TZ S; $\leq 4/2$	AZT S; ≤ 8	PIP S; ≤ 16	PIP/TZ S; $\leq 16/4$	FEP S; ≤ 8	IMP S; ≤ 4	MEM S; ≤ 4
PAO1	2	1	1	8	16	8	4	2	1
PA$\Delta\Delta$	2	1	1	8	16	8	4	1	1
PA$\Delta\Delta$-EV	1	1	1	4	4	4	2	0.5	0.5
PA$\Delta\Delta$-1	4	1	1	8	64	16	4	1	1
PA$\Delta\Delta$-3 (T79A)	4	1	1	4	64	16	4	1	1
PA$\Delta\Delta$-458 (G216S, V330I)	4	2	1	16	16	8	2	1	1
PA$\Delta\Delta$-459 (Q120K, P154L, V213A)	128	32	8	128	32	16	4	1	1
PA$\Delta\Delta$-460 (A89V, V213A, N321S)	32	2	1	16	64	16	4	1	1
PA$\Delta\Delta$-461 (A89V, Q120K, V213A)	128	16	16	32	8	2	8	1	1
PA$\Delta\Delta$-462 (A89V, Q120K, V213A, N321S)	128	8	8	64	64	16	4	1	1
PA$\Delta\Delta$-463 (A89V, H189Y, Q120K, V213A)	64	8	4	128	32	16	4	2	1
PA$\Delta\Delta$-464 (A89V, H189Y, Q120K, V213A, N321S)	64	8	4	16	64	16	4	1	1

^a *bla*_{PDC} allelic variants (PDC-3 and PDC-458 to PDC-464) were cloned into pMBLe vector and transformed into PA $\Delta\Delta$ strain. PA $\Delta\Delta$ expressing PDC variant from PAO1 (i.e. PA $\Delta\Delta$ -PDC-1) or the empty vector (i.e. PA $\Delta\Delta$ -EV) were used as controls. ^b Abbreviations: CAZ, ceftazidime; CTZ, ceftolozane; CTZ/TZ, ceftolozane/tazobactam at 2:1 relation, AZT, aztreonam; PIP, piperacillin; PIP/TAZ, piperacillin/tazobactam at a fix concentration of 4 $\mu\text{g/mL}$; FEP, cefepime; IMP, imipenem; MEM, meropenem. Shown are values from at least two independent experiments. Values of MICs of PA $\Delta\Delta$ -3, PA $\Delta\Delta$ -461 to -463 are highlighted in bold for comparisons with the kinetic parameters obtained for CAZ, CTZ, PIP and IMP antibiotics.

Table 2. Kinetic parameters of PDC variants with different substrates

β -lac ^a	PDC-3			PDC-461			PDC-462			PDC-463		
	K_M	k_{cat}	k_{cat}/K_M	K_M	k_{cat}	k_{cat}/K_M	K_M	k_{cat}	k_{cat}/K_M	K_M	k_{cat}	k_{cat}/K_M
CAZ	57.4 ± 39.3	0.0105 ± 0.000778	0.183 ± 0.138	93.1 ± 40.5	0.465 ± 0.00707	4.99 ± 2.25	23.1 ± 1.98	0.122 ± 0.0103	5.28 ± 0.897	55.0 ± 26.5	0.133 ± 0.0106	2.41 ± 1.35
PIP	18.6 ± 6.84	2.86 ± 1.93	154 ± 160	105 ± 1.55	0.145 ± 0.00705	1.38 ± 0.087 1	9.86 ± 3.23	1.44 ± 0.0574	146 ± 5.38	54.5 ± 34.8	0.801 ± 0.216	14.7 ± 1.33
IMP	10.4 ± 2.96	0.0159 ± 0.00872	1.53 ± 1.27	33.9 ± 21.4	0.00725 ± 0.00247	0.214 ± 0.208	37.3 ± 3.62	0.0389 ± 0.00512	1.03 ± 0.238	35.9 ± 4.76	0.0130 ± 0.00141	0.362 ± 0.0872
CTZ^b	ND	ND	0.040 ± 0.0092	ND	ND	6.1 ± 1.3	ND	ND	0.66 ± 0.14	ND	ND	0.33 ± 0.055

^aKinetic parameters were determined for ceftazidime (CAZ), piperacillin (PIP), imipenem (IMP) and ceftolozane (CTZ). Two independent experiments were carried out and results are expressed as means. Units: K_M (μM), k_{cat} (s^{-1}) and k_{cat}/K_M ($\text{mM}^{-1} \text{s}^{-1}$). ^b Due to the low hydrolysis of ceftolozane, k_{cat}/K_M values were obtained from Lineweaver-Burk plots. ND, not determined.